Midazolam Accord (Midazolam)

Midazolam binds to the benzodiazepine site on the GABA‑A receptor, increasing the frequency of chloride channel opening when GABA binds. This amplifies inhibitory neurotransmission, leading to reduced neuronal excitability, which manifests as sedation, anxiolysis, muscle relaxation, and seizure suppression.

The dosage of Midazolam Accord is individualized and determined by the prescribing clinician based on the indication, route of administration, patient age, weight, and clinical condition. Healthcare professionals calculate the appropriate dose and monitor the patient closely during therapy.

Midazolam is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It should be used in pregnancy only if the potential benefit justifies the risk. The drug is excreted in breast milk, so breastfeeding is generally not recommended while receiving Midazolam.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Compared with other benzodiazepines, Midazolam has a rapid onset and relatively short duration of action, making it suitable for procedural sedation and acute seizure control. Unlike longer‑acting agents such as diazepam, Midazolam allows quicker recovery, but it still shares similar CNS‑depressant properties and interaction profiles.

Midazolam Accord should be stored at ambient temperature, below 25 °C. Keep the vials in their original packaging, protect them from moisture and direct light, and ensure the container remains sealed until use to maintain sterility and potency.

Midazolam can be given by intramuscular, intravenous, or rectal routes, depending on the clinical situation. Intravenous injection provides the fastest onset, while intramuscular or rectal administration may be used when IV access is unavailable or for specific procedural needs.

The most serious risks include severe respiratory depression, profound hypotension, paradoxical reactions such as agitation or aggression, and rare allergic reactions like anaphylaxis. Continuous monitoring of respiratory and cardiovascular status is essential during and after administration.

Midazolam is contraindicated in patients with known hypersensitivity to benzodiazepines, severe acute narrow‑angle glaucoma, and those with significant respiratory compromise without appropriate monitoring. Caution is also advised for individuals with severe hepatic impairment or a history of paradoxical reactions.